Showing 1716 results
-
Press release /51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira®* safety and efficacy profile[1]Sandoz proposed biosimilar adalimumab is currently under…
-
Featured News /
The RUXCOVID clinical trial highlights the Novartis commitment to leverage our expertise and resources to support the global response to the COVID-19 pandemic.
-
Featured News /
-
Press release /If approved, will be first-of-a-kind biosimilar natalizumab in Europe, for use in all indications of reference biologic Positive CHMP opinion based on evidence from extensive analytical…
-
Press release /Divestment includes Xiidra®, on-market treatment for dry eye disease and additional ophthalmic investigational therapiesNovartis advances strategy of focused portfolio and prioritized therapeutic…
-
Press release /Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical dataBreast and gastric cancers are among most common types of cancer, accounting together for nearly half…
-
Press release /European Commission's (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine Biosimilars such as Zessly enable…
-
Press release /
Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)
Biosimilar Ziextenzo® (pegfilgrastim), a long-acting version of supportive oncology medicine filgrastim, is now approved for use in all reference medicine indications [1] Ziextenzo is indicated… -
Press release /Survey data published in JEADV show that patients experienced four different treatments and three medical professionals on average before finding an efficacious therapy[1] New publication also…
-
Press release /Mylight study met its primary efficacy endpoint and showed no clinically meaningful differences to reference afliberceptResults offer hope of new affordable option for patients with nAMD, a leading…